LAS-OI03

• Catalog Number: orb2703917
• Category: Small Molecules
• Description: LAS-OI03 is a novel LNP (Lipid Nanoparticle) vaccine adjuvant and immunotherapeutic agent that combines a dual-adjuvant molecular system comprising CpG 1018 (a TLR9 agonist) and a TLR7/8 activator. This combination elicits robust and long-lasting cellular and humoral immune responses, significantly enhancing the immunogenicity of vaccines. The LNP lipid nanoparticles optimize the uptake and activation of immune cells by efficiently delivering antigens and adjuvant molecules, thereby improving the strength and durability of immune responses. This adjuvant system is suitable for the development of various human prophylactic and therapeutic vaccines, particularly demonstrating notable efficacy in vaccines against complex pathogens such as bacteria, viruses, fungi, and parasites. Research indicates that LNP lipid nanoparticles can enhance the immunostimulatory effects of CpG 1018 by 5-10 times, while the inclusion of the TLR7/8 activator further synergistically boosts Th1-type immune responses and antibody production. In summary, the LNP lipid nanoparticle adjuvant system, with its efficient delivery capability and dual-adjuvant synergy, provides powerful technical support for human vaccines and immunotherapy. It excels in scenarios requiring strong immune protection against complex pathogen infections.
• Note: For research use only